Ftse Mib
34.539,37
0,58%
DAX
18.753,48
0,39%
S&P 500
5.214,08
0,51%
NASDAQ
16.346,26
0,27%
Bitcoin
63.283,20
0,37%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Olema Pharmaceuticals Inc (OLMA) Olema Pharmaceuticals Inc (OLMA) Notizie

OLMA

Olema Pharmaceuticals (OLMA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:OLMA
DataOraFonteTitoloSimboloCompagnia
08/05/202422:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OLMAOlema Pharmaceuticals Inc
08/05/202422:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OLMAOlema Pharmaceuticals Inc
08/05/202422:02GlobeNewswire Inc.Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:OLMAOlema Pharmaceuticals Inc
08/05/202413:02GlobeNewswire Inc.Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual CongressNASDAQ:OLMAOlema Pharmaceuticals Inc
07/05/202423:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OLMAOlema Pharmaceuticals Inc
06/05/202422:00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:OLMAOlema Pharmaceuticals Inc
02/05/202422:37GlobeNewswire Inc.Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:OLMAOlema Pharmaceuticals Inc
01/05/202413:02GlobeNewswire Inc.Olema Oncology to Participate in Upcoming Investor Conferences in MayNASDAQ:OLMAOlema Pharmaceuticals Inc
08/04/202422:30GlobeNewswire Inc.Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual ConferenceNASDAQ:OLMAOlema Pharmaceuticals Inc
11/03/202421:31Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:OLMAOlema Pharmaceuticals Inc
11/03/202421:15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:OLMAOlema Pharmaceuticals Inc
11/03/202421:03GlobeNewswire Inc.Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:OLMAOlema Pharmaceuticals Inc
06/03/202413:03GlobeNewswire Inc.Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 InhibitorsNASDAQ:OLMAOlema Pharmaceuticals Inc
14/02/202422:08Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:OLMAOlema Pharmaceuticals Inc
12/02/202423:16Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:OLMAOlema Pharmaceuticals Inc
12/02/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:OLMAOlema Pharmaceuticals Inc
06/02/202413:01GlobeNewswire Inc.Olema Oncology to Participate in Upcoming Investor ConferencesNASDAQ:OLMAOlema Pharmaceuticals Inc
31/01/202422:21Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:OLMAOlema Pharmaceuticals Inc
08/01/202414:12GlobeNewswire Inc.Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development CandidateNASDAQ:OLMAOlema Pharmaceuticals Inc
05/01/202423:25Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:OLMAOlema Pharmaceuticals Inc
02/01/202422:01GlobeNewswire Inc.Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:OLMAOlema Pharmaceuticals Inc
08/12/202302:30Edgar (US Regulatory)Form 3/A - Initial statement of beneficial ownership of securities: [Amend]NASDAQ:OLMAOlema Pharmaceuticals Inc
05/12/202318:27GlobeNewswire Inc.Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 StudiesNASDAQ:OLMAOlema Pharmaceuticals Inc
28/11/202323:10GlobeNewswire Inc.Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)NASDAQ:OLMAOlema Pharmaceuticals Inc
07/11/202322:02GlobeNewswire Inc.Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:OLMAOlema Pharmaceuticals Inc
01/11/202321:27GlobeNewswire Inc.Olema Oncology to Participate in Upcoming Investor Conferences in NovemberNASDAQ:OLMAOlema Pharmaceuticals Inc
22/10/202308:55GlobeNewswire Inc.Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for PalazestrantNASDAQ:OLMAOlema Pharmaceuticals Inc
18/10/202322:46Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:OLMAOlema Pharmaceuticals Inc
17/10/202313:01GlobeNewswire Inc.Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of DirectorsNASDAQ:OLMAOlema Pharmaceuticals Inc
16/10/202313:02GlobeNewswire Inc.Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO CongressNASDAQ:OLMAOlema Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:OLMA

La tua Cronologia

BIT
ENEL
Enel
BIT
UCG
Unicredit
BIT
LDO
Leonardo
BIT
MB
Mediobanca Banca di Cred...
BIT
G
Generali
BIT
SFER
Salvatore Ferragamo
BIT
STLAM
Stellantis NV
BIT
PIRC
Pirelli & C
BIT
NEXI
Nexi S.p.A
BIT
BPE
Bper Banca
BIT
PRY
Prysmian
BIT
ISP
Intesa Sanpaolo
BIT
ENI
Eni
BIT
RACE
Ferrari NV
BIT
A2A
A2A
BIT
TIT
Telecom Italia
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network